Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This study is testing a three-drug combination — acalabrutinib, venetoclax, and durvalumab — for people with chronic lymphocytic leukemia (CLL), a slow-growing blood cancer. These drugs work through different mechanisms: blocking cancer cell growth signals, triggering cancer cell death, and recruiting the immune system to attack the cancer. **You may be eligible if...** - You are 18 or older and willing to provide consent - You have been diagnosed with chronic lymphocytic leukemia (CLL) meeting standard criteria for treatment - You are willing to attend regular follow-up visits - Your heart, liver, and kidney function are within acceptable limits **You may NOT be eligible if...** - You have serious uncontrolled heart problems such as irregular heartbeat or heart failure - You have active, uncontrolled infections - You are on blood-thinning medications that cannot be safely managed during the study - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.